JP5572786B2 - 天然高麗人参または高麗人参を含む高麗人参類の形成層由来植物幹細胞株を有効成分として含有する老化防止または抗酸化用組成物 - Google Patents
天然高麗人参または高麗人参を含む高麗人参類の形成層由来植物幹細胞株を有効成分として含有する老化防止または抗酸化用組成物 Download PDFInfo
- Publication number
- JP5572786B2 JP5572786B2 JP2011513433A JP2011513433A JP5572786B2 JP 5572786 B2 JP5572786 B2 JP 5572786B2 JP 2011513433 A JP2011513433 A JP 2011513433A JP 2011513433 A JP2011513433 A JP 2011513433A JP 5572786 B2 JP5572786 B2 JP 5572786B2
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- ginseng
- aging
- derived
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000008434 ginseng Nutrition 0.000 title claims description 75
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims description 72
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims description 72
- 239000000203 mixture Substances 0.000 title claims description 44
- 230000003712 anti-aging effect Effects 0.000 title claims description 41
- 230000003078 antioxidant effect Effects 0.000 title claims description 34
- 239000003963 antioxidant agent Substances 0.000 title claims description 20
- 241000208340 Araliaceae Species 0.000 title claims 11
- 241000196324 Embryophyta Species 0.000 title description 14
- 239000004480 active ingredient Substances 0.000 title description 5
- 210000000130 stem cell Anatomy 0.000 title 1
- 239000000284 extract Substances 0.000 claims description 90
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 64
- 240000004371 Panax ginseng Species 0.000 claims description 64
- 230000015572 biosynthetic process Effects 0.000 claims description 60
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 239000002537 cosmetic Substances 0.000 claims description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 12
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 10
- 230000008723 osmotic stress Effects 0.000 claims description 10
- 230000035882 stress Effects 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 5
- 238000004114 suspension culture Methods 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 235000002789 Panax ginseng Nutrition 0.000 claims description 3
- 238000005194 fractionation Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 188
- 239000002609 medium Substances 0.000 description 62
- 239000000243 solution Substances 0.000 description 59
- 230000000694 effects Effects 0.000 description 27
- 239000000126 substance Substances 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- GEWDNTWNSAZUDX-WQMVXFAESA-N (-)-methyl jasmonate Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-WQMVXFAESA-N 0.000 description 9
- GEWDNTWNSAZUDX-UHFFFAOYSA-N methyl 7-epi-jasmonate Natural products CCC=CCC1C(CC(=O)OC)CCC1=O GEWDNTWNSAZUDX-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
- 238000012790 confirmation Methods 0.000 description 8
- 235000020710 ginseng extract Nutrition 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 229930002330 retinoic acid Natural products 0.000 description 8
- 230000009759 skin aging Effects 0.000 description 8
- 229960001727 tretinoin Drugs 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229940089161 ginsenoside Drugs 0.000 description 7
- 229930182494 ginsenoside Natural products 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 239000003617 indole-3-acetic acid Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000001626 skin fibroblast Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- -1 CCC Chemical compound 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940107131 ginseng root Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229930000044 secondary metabolite Natural products 0.000 description 4
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 239000012468 concentrated sample Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 239000005712 elicitor Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 239000005976 Ethephon Substances 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000005595 Picloram Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- MUUDYSFWQUSAOO-UHFFFAOYSA-N cudraflavone C Chemical compound CC(C)=CCC=1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC=1C1=CC=C(O)C=C1O MUUDYSFWQUSAOO-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- NQQVFXUMIDALNH-UHFFFAOYSA-N picloram Chemical compound NC1=C(Cl)C(Cl)=NC(C(O)=O)=C1Cl NQQVFXUMIDALNH-UHFFFAOYSA-N 0.000 description 2
- 238000004161 plant tissue culture Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- JLIDBLDQVAYHNE-YKALOCIXSA-N Abscisic acid Natural products OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000209134 Arundinaria Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000020104 CEBALID syndrome Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102100039397 Gap junction beta-3 protein Human genes 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100061841 Homo sapiens GJB3 gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- UWQYBLOHTQWSQD-UHFFFAOYSA-N Mulberrin Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2CC=C(C)C)=O)=C1OC=2C1=CC=C(O)C=C1O UWQYBLOHTQWSQD-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 235000016976 Quercus macrolepis Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HLVPIMVSSMJFPS-UHFFFAOYSA-N abscisic acid beta-D-glucopyranosyl ester Natural products O1C(CO)C(O)C(O)C(O)C1OC(=O)C=C(C)C=CC1(O)C(C)=CC(=O)CC1(C)C HLVPIMVSSMJFPS-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001647 brassinosteroids Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- ZNJFBWYDHIGLCU-UHFFFAOYSA-N jasmonic acid Natural products CCC=CCC1C(CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229940041260 vanadyl sulfate Drugs 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
- 229910000352 vanadyl sulfate Inorganic materials 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
(a)先天的未分化状態(Innately undifferentiated)であり;
(b)同質の細胞株(homogeneous cell line)であり;及び
(c)多数の液包(vacuole)を有する形態学的特徴を示す。
本願において「形成層(cambium)」とは、植物の幹と根を太くなるようにして、植物が、大きく生長できるようにする組織である。形成層は細胞分裂が最も活発に起きる分裂組織で、植物組織培養の切片体としての使用時において、細胞の高速及び大量生産が可能だと報告されている(韓国登録特許第0533120)。
(a)高麗人参類の形成層含有貯蔵根組織を取得する工程;
(b)前記取得された形成層含有貯蔵根組織に浸透ストレスを加えた後、IAA(Indole-3-acetic acid)またはIBA(Indole-3-butyric acid)を含む培地で培養して、形成層由来細胞株を誘導する工程;及び
(c)前記誘導された形成層由来細胞株を回収する工程。
[1−1]植物材料の用意
図1(a)のAは本発明において使用した天然高麗人参の典型的な特徴を示す。天然高麗人参を用意した後、天然高麗人参の主根部を使うために流水で表面に付いている土やその他の汚れを除去し、液体洗剤を利用して主根の表面を洗った後、流水に放置した。きれいに洗った組織は、クリーンベンチ内に準備された滅菌フラスコに入れて、70%エタノールで30秒乃至1分程度殺菌した。その後、滅菌水で濯いで1%乃至1.5%次亜鉛素酸ナトリウム(sodium hypochlorite, Junsei, Japan)を利用して、5分乃至15分程度で消毒液で処理した。この時、消毒液が効果的に組織内に侵入するようにするためにTWEEN20(Polyoxyethylenesorbitan monolaurate, Junsei, Japan)を数滴落として処理した。この過程が終わると滅菌水で3回乃至5回濯いだ。その後に殺菌処理した組織の褐変化を防止するために抗酸化剤が含まれたBIM(browning inhibition medium)に殺菌された主根を入れて30分乃至1時間程度十分培養し、滅菌されたろ紙に置いて水気を除去した。
前記処理された材料を、褐変されるのを防止するために抗酸化剤が含まれたCS溶液(cutting solution、表2)が入った滅菌皿に置いて、表皮を薄く剥がし半分に分けて、各部分において分裂能が旺盛な形成層の部分が含まれるようにして、横×縦×高さ=0.5〜0.7cm×0.5〜0.7cm×0.2〜0.5mmの大きさに切断した。図1(a)のBは天然高麗人参の主根部において形成層が含まれるように前記の大きさで切断して切片体を製造した様子を示す。
前記実施例1−1で製造された切片体は、分化した組織、即ち、篩部、木部、髄等を壊死させて分裂組織である形成層だけを生存させるために、浸透ストレス処理を行った。前記形成層含有切片体をろ紙が敷かれた前播種培地(培地1、表3)にブロティング(blotting)して、1Mスクロース(Duchefa, Netherland)溶液が入れられたフラスコに入れて、冷蔵状態で16〜24時間浸透ストレス処理した後、0.05Mスクロース溶液(sucrose solution)で5分間、0.1Mスクロース溶液で5分間処理して、高濃度のスクロースによるストレスを解除した。その後、前記浸透ストレスが解除された形成層含有切片体をろ紙が敷かれた前播種培地(培地1)に置いて水気を除去した。
形成層起源の分裂能を有する同質的細胞株を誘導するために、前記実施例1−2で浸透ストレス処理した切片体を細胞株誘導培地(培地2、表4)に播種した。播種に使用された培地は下記表4に示したとおりである。播種された切片体は、22±1℃暗条件で培養した。
前記実施例1−3で誘導された形成層起源の分裂能を有する同質性細胞株を利用して増殖に使用した。培地は下記表6に示した基本塩(salt)組成を元に表7に示したように形成層起源の分裂能を有する同質性細胞株の増殖最適培地を使用した。
前記天然高麗人参形成層由来同質性細胞株を下記表8の液状培地が含まれたフラスコに入れて、暗条件で25±1℃で100rpmの回転攪拌機(shaker)で培養した。継代培養周期は2週間に固定することによって培養細胞が常に対数生長期状態で高活力を維持できるようにした。一方、高麗人参の子葉由来カルス(callus)も<表8>の培地4で培養して、本発明に係る天然高麗人参形成層由来同質性細胞株と比較した。
前記実施例1−5のように14日間懸濁培養した細胞株を利用して、三つの処理区に分けて、実験を行った。
実施例1で製造された三つ処理区の細胞株から下記のとおり有効物質を抽出した。
(1)DMSO抽出物の製造
(i)培養液を除去した細胞株及び凍結乾燥細胞株500gに500mLのDMSOを加えて、50℃で6時間攪拌させながら、溶解させた。
(ii)前記溶解後、3,000gで10分間遠心分離させ上層液を取ることによってDMSO可溶性物質を得た。
(iii)前記で得たDMSO可溶性物質を、回転真空濃縮機を利用して濃縮した。
(iv)濃縮試料を、凍結乾燥器を利用して、乾燥させてDMSO抽出物を得た。
(2)蒸溜水抽出物、メタノール抽出物及びアセトン抽出物の製造
(i)培養液を除去した細胞株及び凍結乾燥細胞株500gに500mLの蒸溜水を加えて、50℃で6時間攪拌させながら溶解させた。
(ii)前記溶解後、3,000gで10分間遠心分離させて上層液を取ることによって蒸溜水可溶性物質を得た。
(iii)前記蒸溜水可溶性物質を得た後、残った蒸溜水不溶性物質に500mLのメタノール(methanol)を添加させて、室温で6時間攪拌して、溶解させた。
(iv)前記溶解後、3,000gで10分間遠心分離させて上層液を取ることによってメタノール可溶性物質を得た。
(v)前記メタノール可溶性物質を得た後、残ったメタノール不溶性物質に500mLのアセトン(acetone)を添加させて、室温で6時間攪拌して溶解させた。
(vi)前記溶解後、3,000gで10分間遠心分離させて、上層液を取ることによってアセトン可溶性物質を得た。
(vii)前記で得た蒸溜水、メタノール、アセトン可溶性物質を、回転真空濃縮機を利用して濃縮した。
(viii)濃縮試料を、凍結乾燥器を利用して、乾燥させて蒸留水、メタノール、アセトンに溶かして、蒸溜水抽出物、メタノール抽出物、アセトン抽出物を得た。
(3)対照群の製造
(i)凍結乾燥した天然高麗人参根500gに500mLのDMSOを加えて、50℃で6時間攪拌させながら、溶解させた。
(ii)前記溶解後、3,000gで10分間遠心分離させ上層液を取ることによってDMSO可溶性物質を得た。
(iii)前記で得たDMSO可溶性物質を、回転真空濃縮機を利用して濃縮した。
(iv)濃縮試料を、凍結乾燥器を利用して、乾燥させて天然高麗人参対照群のDMSO抽出物を得た。
試験に使用された試料の使用濃度範囲を決めるために、下記のとおり細胞毒性を確認した。
3.5%の牛胎児血清が含まれたDMEM(Doubecco’s Modified Eagle’s Media)培地で培養したヒト繊維芽細胞(NHF cell)を96ウェル平板培養器(96-well microtiter plate)に5,000細胞/ウェルになるべく分株し、24時間スターベーション(starvation)した後、実施例2で製造した天然高麗人参の形成層由来同質性細胞株DMSO抽出物及びその培養培地を濃度別(細胞株DMSO抽出物(Wet)及び乾燥細胞株抽出物(Dry)はppm、培養液(Media)は%)に48時間0.5%FBS最小栄養培地状態で処理した。
紫外線露出によってMMPが増加する場合、増加したMMPsは皮膚のコラーゲンを分解して、皮膚のシワを形成させるため、紫外線によって増加したMMP−1発現が天然高麗人参形成層由来同質性細胞株抽出物またはその培養液によって抑制される効果を確認するために以下の実験を行った。
NHF(p6)を12ウェルプレートに75,000細胞/ウェルになるべく分株し24時間スターベーション(starvation)した後、40mJのUVBを照射して、各試料を濃度別に48時間処理して、キット(Amersham, RPN 2610)を利用して、実験を行った。陽性対照群としては10uMのレチノイン酸(retinoic acid)を使用した。
紫外線によって増加した活性酸素が天然高麗人参形成層由来同質性細胞株抽出物またはその培養液によって抑制される効果を確認するために、96ウェル black plateにHaCaT cell(German Cancer Research Institute, Heidelberg, Germany)を30,000細胞/ウェルになるように分株し、各試料を濃度別に3時間処理した。3時間後、HBSSで1度洗浄してDCF50uMを各ウェルに処理して37度で20分間反応させた。HBSSで2度洗浄した後、Luminatorを利用して、初期吸光度を測定した。これにUVB30mJを照射した後、37度で2時間培養後、吸光度を測定した。Controlは試料及びUVBを添加しないものであり、UVBは試料の添加なしにUVBだけで処理したものを示す。
天然高麗人参抽出物のジンセノーサイド成分が皮膚老化防止及び抗酸化に効果があると知られているが、そこで本発明に係る細胞株抽出物及びその培養液の皮膚老化防止及び抗酸化効果がこのようなジンセノーサイド成分の効果によるものであるか否かを調べるためにジンセノーサイド含有量を測定した。即ち、実施例2で製造した工程別天然高麗人参の形成層由来同質性細胞株と天然高麗人参は凍結乾燥させた後、凍結乾燥された細胞株20mgをメタノール600uLに1時間抽出して遠心分離後、上層液を分離する。分離した抽出物のジンセノーサイド含有量はUPLCを利用して測定し、含有量は標準Re、Rb1、Rb2、Rdと比較して示した。また、培養液は、Elicitation1工程の培養液を0.2umシリンジフィルターを利用してろ過した後、HPLCを利用して測定し、含有量は標準Re、Rb1、Rb2、Rdと比較して示した。
本発明に係る天然高麗人参形成層由来細胞株の老化防止活性と露地天然高麗人参の老化防止活性を比較するために、韓国慶煕大学皮膚生命工学センターに依頼して、下記のとおり前記センター標準業務指針に従って実験を行った。
本発明に係る天然高麗人参形成層由来細胞株の抗酸化活性と露地天然高麗人参の抗酸化活性を比較するために、韓国慶煕大学皮膚生命工学センターに依頼して、下記のとおり前記センター標準業務指針に従って実験を行った。
[製剤例1]錠剤の製造
実施例2で製造された細胞株抽出物100mgをとうもろこし澱粉100mg、乳糖100mg及びステアリン酸マグネシウム2mgを混合して、通常の錠剤製造方法によって製造した。
実施例2で製造された細胞株抽出物500mgを軟質ゼラチンカプセルに充填して、カプセル剤を製造する。
実施例1で製造された細胞株1g、異性化糖10g、マンニトール5g、適量の精製水の含有量で通常の液製剤の製造方法によって100mLのシロップ剤を製造した。
実施例2で製造された細胞株抽出物200mgを、ポリオキシエチレン水素化カストロオイルを含有する生理食塩水200mgに加熱溶解させて、混合抽出物を0.1%の濃度で含有する注射剤を製造した。
[剤形例1]柔軟化粧水(スキンローション)の製造
[製造例1]
実施例1で製造した細胞株200mgを96mLの水に溶解させた後、補助剤としてビタミンC500mg、矯味剤としてクエン酸、オリゴ糖を各々1g加え、保存剤として安息香酸ナトリウム0.05gを加えた後、精製水を加えて、全量を100mLにして、機能性飲み物を製造した。
実施例2で製造した細胞株抽出物200mgを96mLの水に溶解させた後、補助剤としてビタミンC500mg、矯味剤としてクエン酸、オリゴ糖を各々1g加え、保存剤として安息香酸ナトリウム0.05gを加えた後、精製水を加えて、全量を100mLにして、機能性飲み物を製造した。
Claims (10)
- 高麗人参類の形成層から誘導され、以下の特性を有する細胞株の乾燥細胞、その破砕物、及びその抽出物のいずれか一つ以上を含有する老化防止または抗酸化用組成物:
(a)先天的未分化状態であり;そして
(b)同質の細胞株である。 - 前記細胞株は以下の特性を追加的に有することを特徴とする請求項1に記載の老化防止または抗酸化用組成物:
(a)懸濁培養時に単細胞状態で存在し;
(b)高麗人参類の形成層以外の組織由来細胞株と比べて、バイオリアクターにおいて剪断ストレスに対して低い感受性を有し;及び
(c)高麗人参類の形成層以外の組織由来細胞株に比べて、生長速度が速く、安定して培養される。 - 前記細胞株は以下の工程を含む分離方法によって取得されたことを特徴とする請求項1に記載の老化防止または抗酸化用組成物:
(a)高麗人参類の形成層含有貯蔵根組織を取得する工程;
(b)前記取得された形成層含有貯蔵根組織に浸透ストレスを加えた後、IAAまたはIBAを含む培地で培養して、形成層由来細胞株を誘導する工程;及び
(c)前記誘導された形成層由来細胞株を回収する工程。 - 高麗人参類は、天然高麗人参または高麗人参であることを特徴とする請求項1〜3のいずれか一項に記載の老化防止または抗酸化用組成物。
- 前記抽出物は蒸溜水、アルコール、アセトン、DMSO及びこれらの混合溶媒からなる群から選択される溶媒を利用して抽出されたことを特徴とする請求項1〜4のいずれか一項に記載の老化防止または抗酸化用組成物。
- 前記抽出物は、前記細胞株を蒸溜水、メタノール及びアセトンで順次溶媒分画して獲得されたことを特徴とする請求項1〜4のいずれか一項に記載の老化防止または抗酸化用組成物。
- 高麗人参類の形成層から誘導され、以下の特性を有する細胞株の乾燥細胞、その破砕物、及びその抽出物のいずれか一つ以上を含有する老化防止用化粧料組成物:
(a)先天的未分化状態であり;そして
(b)同質の細胞株である。 - 前記細胞株は以下の特性を追加的に有することを特徴とする請求項7に記載の老化防止用化粧料組成物:
(a)懸濁培養時に単細胞状態で存在し;
(b)高麗人参類の形成層以外の組織由来細胞株と比べて、バイオリアクターにおいて剪断ストレスに対して低い感受性を有し;及び
(c)高麗人参類の形成層以外の組織由来細胞株に比べて、生長速度が速く、安定して培養される。 - 前記細胞株は以下の工程を含む分離方法によって取得されたことを特徴とする請求項7又は8に記載の老化防止用化粧料組成物:
(a)高麗人参類の形成層含有貯蔵根組織を取得する工程;
(b)前記取得された形成層含有貯蔵根組織に浸透ストレスを加えた後、IAAまたはIBAを含む培地で培養して、形成層由来細胞株を誘導する工程;及び
(c)前記誘導された形成層由来細胞株を回収する工程。 - 前記組成物はMMP−1生成を抑制することを特徴とする請求項7〜9のいずれか一項に記載の老化防止用化粧料組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0056008 | 2008-06-13 | ||
KR20080056008 | 2008-06-13 | ||
PCT/KR2009/003176 WO2009151302A2 (ko) | 2008-06-13 | 2009-06-12 | 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 노화방지 또는 항산화용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011522884A JP2011522884A (ja) | 2011-08-04 |
JP5572786B2 true JP5572786B2 (ja) | 2014-08-20 |
Family
ID=41417270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011513433A Active JP5572786B2 (ja) | 2008-06-13 | 2009-06-12 | 天然高麗人参または高麗人参を含む高麗人参類の形成層由来植物幹細胞株を有効成分として含有する老化防止または抗酸化用組成物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20110097310A1 (ja) |
EP (1) | EP2308462A2 (ja) |
JP (1) | JP5572786B2 (ja) |
KR (1) | KR101126315B1 (ja) |
CN (1) | CN102159182B (ja) |
AU (1) | AU2009258386B2 (ja) |
BR (1) | BRPI0909876A2 (ja) |
CA (1) | CA2732058C (ja) |
RU (1) | RU2500386C2 (ja) |
WO (1) | WO2009151302A2 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1951863B1 (en) | 2005-10-31 | 2015-07-08 | Unhwa Corporation | Stability of secondary metabolite mass production through syncronized plant cell cultures |
US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
KR101064518B1 (ko) * | 2007-09-21 | 2011-09-19 | 주식회사 운화 | 저장근을 가지는 초본식물의 형성층 유래 식물줄기세포주 및 이의 분리방법 |
WO2009151302A2 (ko) | 2008-06-13 | 2009-12-17 | 주식회사 운화바이오텍 | 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 노화방지 또는 항산화용 조성물 |
KR101179171B1 (ko) | 2008-08-14 | 2012-09-03 | 주식회사 운화 | 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 간질환의 예방 또는 치료용 조성물 |
EP2363137A4 (en) | 2008-09-30 | 2012-08-01 | Unhwa Corp | COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS WITH PLANT GINSENG VEGETABLE GAMBLING LINE FROM THE BAMBIUM OF PANAX GINSENG OR GINSENG AS AN ACTIVE SUBSTANCE |
KR101141166B1 (ko) * | 2009-05-26 | 2012-05-02 | 주식회사 운화 | 은행나무과의 형성층 유래 식물줄기세포 및 이의 분리방법 |
KR101233991B1 (ko) * | 2010-03-18 | 2013-02-18 | 동국대학교 산학협력단 | 발효홍삼의 제조방법 |
KR101233987B1 (ko) * | 2010-03-18 | 2013-02-18 | 동국대학교 산학협력단 | 발효홍삼의 제조방법 |
CN103841956B (zh) * | 2011-03-27 | 2016-11-09 | 奥麒化工有限公司 | 调节表观遗传dna甲基化以导致细胞采取与年轻细胞相关的dna甲基化模式 |
KR101321011B1 (ko) * | 2011-11-30 | 2013-10-23 | 주식회사 엘지생활건강 | 피부결 개선용 조성물 |
WO2013102882A2 (en) | 2012-01-05 | 2013-07-11 | L'oreal | Cosmetic use of dedifferentiated plant cells |
FR3007982B1 (fr) | 2013-07-05 | 2015-08-21 | Oreal | Stabilisation des cellules dedifferenciees de rose. |
JP6483240B2 (ja) * | 2014-08-22 | 2019-03-13 | ウェルキー ホールディングス リミテッドWellkey Holdings Limited | 希少ジンセノサイドを高含量で含有する、山参もしくは高麗人参を含む高麗人参類の抽出物または高麗人参類の形成層由来植物幹細胞もしくはその抽出物の製造方法 |
CN104498425B (zh) * | 2014-11-28 | 2016-03-02 | 广州赛莱拉干细胞科技股份有限公司 | 雪莲干细胞的分离培养方法及在制备抗衰老产品中的应用 |
KR101836354B1 (ko) * | 2015-03-09 | 2018-03-09 | 주식회사 한국화장품제조 | 산삼배양근 오일을 유효성분으로 포함하는 화장료 조성물 |
EP3135341B1 (en) | 2015-08-27 | 2019-02-20 | Latvijas Universitate | Cosmetic skin whitening compositions containing extracts derived from in vitro propagated hypericum hirsutum |
CN105748343B (zh) * | 2016-02-25 | 2018-06-15 | 广州市科玮生物技术有限公司 | 一种天然植物提取物组合物及其在化妆品中的应用 |
CN105661240A (zh) * | 2016-03-10 | 2016-06-15 | 浙江博士园生物技术有限公司 | 一种北虫草饮料及其制备方法 |
CN105919886A (zh) * | 2016-06-13 | 2016-09-07 | 广东万海细胞生物科技有限公司 | 一种速效修复皱纹的乳液及其制备方法 |
CN105963211A (zh) * | 2016-07-02 | 2016-09-28 | 广东万海细胞生物科技有限公司 | 一种深层护理面膜膏及其制备方法 |
KR101759650B1 (ko) * | 2017-04-03 | 2017-07-19 | 연세대학교 산학협력단 | 오시멘(Ocimene) 또는 이의 염을 유효성분으로 함유하는 피부주름 개선, 보습, 탄력증진, 각질제거, 홍반억제 또는 피부광노화 개선용 조성물 |
CN107616964A (zh) * | 2017-09-15 | 2018-01-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种高丽参干细胞护肤组合物及其制备方法 |
CN107789306A (zh) * | 2017-10-31 | 2018-03-13 | 广州赛莱拉干细胞科技股份有限公司 | 一种高丽参干细胞提取物滋润保湿护肤组合物及其制备方法 |
KR102655941B1 (ko) * | 2018-08-13 | 2024-04-11 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 항산화 조성물 |
KR102394647B1 (ko) * | 2018-08-29 | 2022-05-09 | (주)아모레퍼시픽 | 인삼 세포 파쇄물을 포함하는 피부 탄력 증진용 또는 피부 주름 개선용 조성물 |
KR102187618B1 (ko) * | 2018-11-01 | 2020-12-07 | (주)아모레퍼시픽 | 수크로스, 인돌-3-아세트산 및 로즈힙 열매 추출물의 혼합물을 포함하는 피부 외용제 조성물 |
JP2020200298A (ja) * | 2019-06-13 | 2020-12-17 | 株式会社再春館製薬所 | 皮膚外用剤 |
FR3105259B1 (fr) | 2019-12-19 | 2022-03-11 | Oreal | Cellules végétales dédifférenciées non élicitées deLavandula angustifolia, ses extraits et ses utilisations cosmétiques |
KR20210156482A (ko) * | 2020-06-18 | 2021-12-27 | 성균관대학교산학협력단 | 라이소인지질 함유 수용성 안정화 조성물 및 이의 제조 방법 |
CN114053204A (zh) * | 2021-11-01 | 2022-02-18 | 上海普瑞康企业发展有限公司 | 一种含长白山野山参细胞水提取物的抗衰霜 |
CN117362110B (zh) * | 2023-11-02 | 2024-02-13 | 烟台众德集团有限公司 | 一种基于壳寡糖的缓释肥料及其制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61173774A (ja) * | 1985-01-26 | 1986-08-05 | Nissho Kisetsu:Kk | 生薬成分を含む生物組織の培養法 |
JPS6239529A (ja) * | 1985-08-13 | 1987-02-20 | Nitto Electric Ind Co Ltd | 薬用人参エキスの製造方法 |
FR2647342B1 (fr) * | 1989-05-23 | 1994-05-27 | Sanofi Sa | Composition cosmetique s'opposant au vieillissement de la peau |
DE4028622C2 (de) * | 1990-09-08 | 1994-01-27 | Suwelack Nachf Dr Otto | Verfahren zum Herstellen von Kollagenschwämmen |
JPH10182412A (ja) * | 1996-12-27 | 1998-07-07 | Kose Corp | 外用剤 |
KR100253842B1 (ko) | 1997-09-12 | 2000-07-01 | 유상옥 | 멀베린을 함유하는 미백화장료 |
KR19990057560A (ko) * | 1997-12-30 | 1999-07-15 | 박명규 | 인삼의 부위별 유해산소제거효소 함량증가 효과 검증방법 및 항 산화 효능을 갖는 인삼 엑스 |
KR100361433B1 (ko) | 1998-05-28 | 2003-01-24 | 주식회사 태평양 | 인삼추출물을함유하는피부노화방지용화장료조성물 |
KR100295875B1 (ko) | 1998-11-07 | 2001-11-14 | 정찬복 | 초두구추출물을함유하는화장료 |
KR20030009454A (ko) * | 2000-05-31 | 2003-01-29 | 카가쿠키쥬쯔 신코지교단 | 진세노사이드Rb1으로 된 피부조직 재생촉진제 |
KR100365071B1 (ko) * | 2000-12-28 | 2002-12-18 | 주식회사 태평양 | 인삼 어글리콘을 함유하는 피부 노화방지용 화장료 조성물 |
KR100440193B1 (ko) | 2001-01-08 | 2004-07-12 | 김기창 | 탄성밴드 제조방법 및 그 탄성밴드 |
KR100479803B1 (ko) * | 2002-04-08 | 2005-03-30 | 홍림통산(주) | 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물 |
KR100533120B1 (ko) | 2003-06-16 | 2005-12-14 | 주식회사 운화 바이오텍 | 형성층을 이용한 식물세포배양 방법 |
EP1951863B1 (en) * | 2005-10-31 | 2015-07-08 | Unhwa Corporation | Stability of secondary metabolite mass production through syncronized plant cell cultures |
WO2009151302A2 (ko) | 2008-06-13 | 2009-12-17 | 주식회사 운화바이오텍 | 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 노화방지 또는 항산화용 조성물 |
-
2009
- 2009-06-12 WO PCT/KR2009/003176 patent/WO2009151302A2/ko active Application Filing
- 2009-06-12 BR BRPI0909876-3A patent/BRPI0909876A2/pt not_active Application Discontinuation
- 2009-06-12 CA CA2732058A patent/CA2732058C/en active Active
- 2009-06-12 US US12/997,858 patent/US20110097310A1/en not_active Abandoned
- 2009-06-12 RU RU2011100824/15A patent/RU2500386C2/ru active
- 2009-06-12 EP EP09762688A patent/EP2308462A2/en not_active Withdrawn
- 2009-06-12 CN CN200980130417.7A patent/CN102159182B/zh active Active
- 2009-06-12 AU AU2009258386A patent/AU2009258386B2/en active Active
- 2009-06-12 JP JP2011513433A patent/JP5572786B2/ja active Active
- 2009-06-12 KR KR1020090052340A patent/KR101126315B1/ko active IP Right Grant
-
2013
- 2013-04-16 US US13/863,817 patent/US9095532B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2732058C (en) | 2014-09-23 |
KR20090129963A (ko) | 2009-12-17 |
JP2011522884A (ja) | 2011-08-04 |
CN102159182B (zh) | 2014-09-03 |
WO2009151302A9 (ko) | 2010-06-10 |
KR101126315B1 (ko) | 2012-03-23 |
RU2011100824A (ru) | 2012-08-10 |
RU2500386C2 (ru) | 2013-12-10 |
US9095532B2 (en) | 2015-08-04 |
EP2308462A2 (en) | 2011-04-13 |
WO2009151302A3 (ko) | 2010-03-11 |
CA2732058A1 (en) | 2009-12-17 |
AU2009258386B2 (en) | 2013-04-04 |
AU2009258386A1 (en) | 2009-12-17 |
US20130302287A1 (en) | 2013-11-14 |
CN102159182A (zh) | 2011-08-17 |
BRPI0909876A2 (pt) | 2020-09-01 |
US20110097310A1 (en) | 2011-04-28 |
WO2009151302A2 (ko) | 2009-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5572786B2 (ja) | 天然高麗人参または高麗人参を含む高麗人参類の形成層由来植物幹細胞株を有効成分として含有する老化防止または抗酸化用組成物 | |
KR101141166B1 (ko) | 은행나무과의 형성층 유래 식물줄기세포 및 이의 분리방법 | |
JP2006316073A (ja) | 抽出物、医薬組成物、化粧用組成物、及びこれら組成物の製造方法 | |
KR102198872B1 (ko) | 미네랄을 이용한 진정 및 재생효과를 갖는 병풀 무균 숙성액 및 이의 제조방법 | |
KR102381564B1 (ko) | 한국산 산삼 캘러스 세포배양에 의하여 얻어진 고수율 진세노사이드 생합성유도 조성물 및 이의 용도 | |
KR101777836B1 (ko) | 은행나무과의 형성층 유래 식물줄기세포를 유효성분으로 함유하는 항노화용 조성물 | |
JP6154567B2 (ja) | 保湿剤およびその製造方法ならびに当該保湿剤からなる化粧料 | |
US11096885B2 (en) | Composition for enhancing skin elasticity or improving skin wrinkles comprising ginseng cell lysate | |
KR102229482B1 (ko) | 피부 보호효과를 갖는 비파나무 잎 미네랄당 숙성액 및 이의 제조 방법 | |
KR100937255B1 (ko) | 흑마늘을 이용한 저분자량의 분획된 생리활성 농축분획액의제조방법 | |
KR20130050173A (ko) | 맹그로브 캘러스 추출물을 함유하는 피부 외용제 조성물 | |
KR20180042541A (ko) | 수선화 비늘줄기 발효 초고압 추출물을 함유하는 화장료 조성물 | |
CN116159006B (zh) | 一种富含多种牡丹成分的组合物及其应用 | |
KR101291460B1 (ko) | 섬오갈피나무의 캘러스 추출물을 함유하는 피부 외용제 조성물 | |
KR102701236B1 (ko) | 시계초꽃 유래 락티플랜티바실러스 플란타룸 균주에 의한 시계초 발효물을 이용한 천연물의 숙성 방법 및 이를 활용한 자외선 노출에 의한 피부 과민 반응 개선용 조성물 | |
WO2023042826A1 (ja) | ブナ科植物由来カルス、カルス抽出物、それを用いた方法および化粧品組成物 | |
JP7378217B2 (ja) | ヤグルマギク発酵液及びその製造方法、並びに化粧料 | |
KR20230138739A (ko) | 인삼 세포 추출물을 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
KR101593905B1 (ko) | 산삼세포의 이차 대사산물 생성 촉진방법 | |
KR20240020034A (ko) | 알로에 형성층 유래 알로에 줄기세포 추출물의 제조방법 및 이에 따라 제조된 추출물을 포함하는 피부 항산화 조성물 | |
KR20220023659A (ko) | 금령자와 현호색의 혼합 발효물을 포함하는 기능성 화장료 조성물 | |
JP2023049333A (ja) | 育毛剤及び毛乳頭細胞増殖促進剤 | |
JPWO2019123893A1 (ja) | 抗酸化剤又は育毛剤の製造方法、及び、該製造方法で製造された抗酸化剤又は育毛剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130415 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130422 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130515 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130617 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131111 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140107 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140311 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140410 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140410 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5572786 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |